Skip to main content

Table 1 Demographics information of included studies

From: Associations of serum low-density lipoprotein and systolic blood pressure levels with type 2 diabetic patients with and without peripheral neuropathy: systemic review, meta-analysis and meta-regression analysis of observational studies

First author (Ref.) Year SS Gender (M/F) Mean Duration of DM (Months) Population (ethnicity) Study design NOSa
Zhao W. et al. [4] 2016 469 283/186 120 China (A) Cross-sectional 8
Wu F. et al. [5] 2017 1134 645/489 78 China (A) Cross-sectional 8
ALMA R. et al. [6] 2014 82 52/30 99.6 Canada (AM) Case control 8
Yang J. et al. [7] 2017 1511 743/768 105 China/A Cross-sectional 8
Bilir B. et al. [8] 2016 99 47/52 NA Turkey/A Clinical study 7
Sharon L. et al. [9] 2017 1981 1001/980 144 Singapore/A Cross-sectional 8
Yong J. et al. [10] 2015 180 96/84 135.6 China/A Case control 8
Su J. et al. [11] 2018 563 299/264 67.2 China/A Cross-sectional 8
Zhang Y. et al. [12] 2017 1059 589/470 102.7 China/A Case control 7
Won J. et al. [13] 2012 3999 1939/2060 121.2 Korea/A Cross-sectional 7
Lin X. et al. [53] 2017 200 123/77 109 China/A Cross-sectional 8
Qiao X. et al. [54] 2017 185 79/106 123 China/A Cross-sectional 8
Sadosky A. et al. [34] 2014 323,378 151,927/171451 NA USA/NA Retrospective 8
YM. S. et al. [55] 2018 982 497/485 64 China/A Cross-sectional 7
Khawaja N. et al. [56] 2018 1003 480/523 120 Jordan/A Cross-sectional 7
Zhang Q. et al. [57] 2018 254 127/127 138 China/A Case control 8
Jangh M. et al. [58] 2006 810 289/521 98.4 Iran/A Cross-sectional 8
Kim S. et al. [59] 2013 1338 593/745 145 Korea/A Cross-sectional 8
Bansal D. et al. [14] 2014 2006 989/1017 104.4 India/A Cross-sectional 8
Buraczy M. et al. [15] 2016 1244 594/650 153.6 Poland/EU Case control 8
Luo Y. et al. [16] 2015 412 233/179 150 China/A Cross-sectional 7
Ren Z. et al. [17] 2015 787 395/392 179.4 China/A Case control 8
Andersen S. et al. [44] 2018 1256 735/521 156 Denmark/EU Cohort study 7
Anastasi T. et al. [45] 2017 381 220/161 147 Greece/EU Cross-sectional 8
Xu T. et al. [46] 2017 537 161/376 NA China/A Observational 8
Zhu T. et al. [52] 2014 64 31/33 NA China/A Cross-sectional 8
Deng W. et al. [51] 2014 202 115/87 98 China/A Cross-sectional 8
Thainá R. et al. [50] 2018 426 162/264 92 Brazil/SA Cohort study 7
Miric D. et al. [35] 2016 80 33/47 72 Serbia/EU Case control 7
Hussain G. et al. [42] 2013 86 38/48 96 India/A Cross-sectional 7
Li L. et al. [43] 2014 3359 1607/1268 91 China/A Cross-sectional 8
Pai Y. et al. [36] 2018 2837 1661/1186 130.4 Taiwan/A Cross-sectional 7
Xu F. et al. [48] 2014 90 46/44 66 China/A Cross-sectional 8
Wang H. et al. [37] 2013 207 88/119 NA China/A Case control 7
Wang H. et al. [40] 2012 261 124/137 76.9 China/A Case control 8
Pai Y. et al. [39] 2018 626 333/293 184.8 Taiwan/A Case control 8
Mao F. et al. [22] 2018 950 555/395 106.2 China/A Cross-sectional 8
Hoque S. et al. [33] 2016 400 166/234 72 Bangladesh/A Cross-sectional 8
  1. Abbreviations: Ref. reference, SS sample size, M male, F femal, AM amaricen, A Asian, EU europea, NOS Newcastle-Ottawa scale, NA not avalibale
  2. aThe quality of non-randomized studies will be appraised using the Newcastle-Ottawa scale (NOS), categorized into three groups: the selection of the study groups; the comparability of the groups; as well as the ascertainment of either the exposure or outcome of interest for case-control or cohort studies respectively
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us